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Genetic analyses have shaped much of our understanding of cancer. However, it is becoming increasingly
clear that cancer cells display features of normal tissue organization, where cancer stem cells (CSCs) can
drive tumor growth. Although often considered as mutually exclusive models to describe tumor heterogene-
ity, we propose that the genetic and CSC models of cancer can be harmonized by considering the role of
genetic diversity and nongenetic influences in contributing to tumor heterogeneity. We offer an approach
to integrating CSCs and cancer genetic data that will guide the field in interpreting past observations and
designing future studies.Introduction
Despite advances in cancer treatment, many patients still fail
therapy, resulting in disease progression, recurrence, and
reduced overall survival. Historically, much focus has been on
the genetic and biochemical mechanisms that cause drug
resistance. However, cancer is widely understood to be a het-
erogeneous disease and there is increasing awareness that
intratumoral heterogeneity contributes to therapy failure and dis-
ease progression (Hanahan and Weinberg, 2011). A tumor is not
simply a ‘‘bag’’ of homogeneousmalignant cells. Rather, a tumor
is a complex ecosystem containing tumor cells, as well as
various infiltrating endothelial, hematopoietic, stromal, and other
cell types that can influence the function of the tumor as a whole.
These extraneous cell types can influence tumor cells directly
and can create metabolic changes such as a hypoxic environ-
ment and nutrient fluctuations, which contribute to heterogeneity
in the function of malignant cells. By functioning as a complex
ecosystem, overall tumor fitness may be enhanced, ultimately
impacting therapy failure (Junttila and de Sauvage, 2013). Aside
from these non-cell-autonomous effects, even individual malig-
nant cells within a tumor can possess variation in growth,
apoptosis, metabolism, and other ‘‘hallmarks of cancer.’’ How-
ever, the mechanisms driving intratumoral variation in cellular
function have, until recently, been uncertain.
Three avenues of cancer research are coming together to pro-
vide increasing clarity to the underlying mechanisms of tumor
heterogeneity and uncovering how these are linked to therapy
resistance, tumor progression, and recurrence. Advanced
genome sequencing has demonstrated that cancer within a sin-
gle patient is a heterogeneousmixture of genetically distinct sub-
clones that arise through branching evolution (Burrell et al., 2013;
Greaves and Maley, 2012). The unique driver mutations within
each subclone can impact the cancer hallmarks differently,
thereby contributing to functional heterogeneity. In parallel,
strong evidence is emerging that nongenetic determinants,
largely related to developmental pathways and epigenetic mod-
ifications (DNA methylation, histone modification, chromatin
openness, microRNA [miRNA], and other noncoding RNA)
contribute to functional heterogeneity (Dick, 2008; Meacham
and Morrison, 2013; Nguyen et al., 2012). These determinants
are generally ascribed to the maintenance of normal tissuestem cell hierarchies. Similarly, nongenetic determinants create
hierarchically organized tumor tissues where a subpopulation
of self-renewing cancer stem cells (CSCs) sustains the long-
term clonal maintenance of the neoplasm. Although consider-
able controversy remains as to which tumor types are
hierarchically organized and how best to define CSCs, this
developmental and/or hierarchical model has generated consid-
erable interest because CSCs appear to possess properties that
make them clinically relevant. Evidence from both experimental
models and clinical studies indicate that CSCs survive many
commonly employed cancer therapeutics. Moreover, the prop-
erties and transcriptional signatures specific to CSC are highly
predictive of overall patient survival pointing to their clinical rele-
vance. Although this area will not be discussed in our review, an
additional promising avenue is the recognition that there are
many nontumor cell elements associated with tumors, referred
to collectively as the tumor microenvironment (TME) (Hanahan
and Coussens, 2012). The juxtaposition of a tumor cell with the
TME influences the function of that cell, resulting in significant
variation in cellular function. The complexity imposed by the
TME is amplified due to crosstalk between tumor cells and the
TME. The TME plays a role in adaptive drug resistance, as cells
of the same genetic make-up can be sensitive or resistant to
drugs depending on the context they are in. Recent studies
also point to the potential for the TME to initiate stem cell-like
programs in cancer cells (Charles et al., 2010; Vermeulen et al.,
2010). Collectively, all three mechanisms are strongly linked to
therapy failure and tumor recurrence and all are important deter-
minants of tumor fitness (Figure 1).
We will focus our Review on the genetic and developmental
mechanisms that generate tumor heterogeneity, and we will
emphasize human studies. Although often considered as mutu-
ally exclusive models to describe tumor heterogeneity, we pro-
pose that the genetic and developmental and/or hierarchical
models of cancer can be harmonized. Indeed, recent findings
in leukemia and solid tumors indicate that gene-expression sig-
natures specific to CSC and normal stem cells are highly prog-
nostic for outcome across a wide spectrum of patients with
diverse driver mutations (Bartholdy et al., 2014; Eppert et al.,
2011; Gentles et al., 2010; Merlos-Sua´rez et al., 2011), suggest-
ing that stemness is a central biological property or processCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 275
Figure 1. Stemness as a Guiding Principle that Governs Therapeutic
Response
Three fields in biology—cancer genetics, epigenetics, and microenviron-
ment—are coming together to provide increasing clarity to the processes that
determine stemness and in turn influence clinical outcome. These three factors
can influence stemness simultaneously, but they can also act independently
over time. Through evolutionary time, different forces can impact a cell’s
stemness properties and thereby shape tumor progression and therapeutic
response.
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hypothesis is that three facets—genetic diversity, epigenetics,
and the TME—contribute to tumor heterogeneity, and the clinical
relevance of each is related to the extent to which it impinges on
stemness and thereby influences patient survival (Figure 1).
Defining Stemness
Themodern era of stem cell research began in 1961 with the pio-
neering studies of Till and McCulloch who developed a clonal
in vivo repopulation assay and used it to show that a single he-
matopoietic cell had multilineage differentiation potential while
still retaining the property of self-renewal. Although multilineage
differentiation potential is often considered a stem cell property,
studies in the hematopoietic system have clearly identified
distinct cells capable of both repopulation and multilineage
potential but lacking self-renewal potential. Thus, the cardinal
property of a stem cell is self-renewal, whether normal or malig-
nant. Self-renewal is the key biological process where, upon cell
division, a stem cell produces one (asymmetric division) or two
(symmetric division) daughters that retain the capacity for self-
renewal, ensuring that the stem cell population is maintained
or expanded for long-term clonal growth. Operationally, the
gold standard measure of a stem cell is maintenance of long-
term clonal growth in functional repopulation assays, involving
either transplantation into serial recipients or in situ tracking.
Indeed the lack of adherence to this principle has generated
much confusion in the CSC field. Many studies employ surrogate
in vitro assays such as serial replating of tumorspheres or report
on serial passage of bulk tumor cells. However, only clonal serial
in vivo repopulation assays can formally test self-renewal of stem
cells. The molecular programs that underlie the stem cell state276 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.are only just emerging as studies are defining critical epigenetic
states and the transcription factors and epigenetic modifiers
(e.g., Polycomb complexes and miRNA) that are responsible
for endowing self-renewal to a cell. The term ‘‘stemness’’ is
increasingly being used in the literature to refer collectively to
the integrated functioning of molecular programs that govern
and maintain the stem cell state. We will adopt the term ‘‘stem-
ness’’ throughout this review to denote this meaning.
Cancer Stem Cells and Tumor-Initiating Cells
By definition, both CSCs and normal tissue stem cells possess
self-renewal capacity; however, self-renewal is typically deregu-
lated in CSCs. Formany cancers, CSCs represent a distinct pop-
ulation that can be prospectively isolated from the remainder of
the tumor cells and can be shown to have clonal long-term repo-
pulation and self-renewal capacity—the defining features of a
CSC (Clarke et al., 2006; Nguyen et al., 2012). However, in
some cancer types it has not been possible to distinguish
CSCs from non-CSCs because most cells have CSC function.
Such tumors seem to be homogeneous or possess a very
shallow hierarchy. As well, some evidence is emerging that
certain cancer cells exhibit plasticity by reversibly transitioning
between a stem and non-stem-cell state (although this is a
controversial and intensely debated topic). Thus, even though
some tumors may not be organized into a rigid hierarchy, the
stemness state contributes a variety of functions that enable
cells to survive therapy. A key proposition of our review is that
the determinants of stemness are the core contributors that
affect therapy failure, regardless of whether these determinants
are present within a transitory state or in well-defined CSC pop-
ulations. Like CSCs, transitory cells also possess clonal tumor-
initiation capacity; however, prospective isolation is difficult.
Thus, in terms of nomenclature they pose a problem and formally
they should not be termed CSCs, a term restricted to cases
where self-renewing CSC can be prospectively purified. We
and others refer to such cells on the basis of the functional
tumor-initiating cell (T-IC) or leukemia-initiating cell (L-IC) assays
that identify them. T-IC or L-IC are defined by their ability to: (1)
generate a xenograft that is representative of the parent tumor,
(2) self-renew as demonstrated by serial passage in a xenograft
assay at clonal cell doses, and (3) give rise to daughter cells that
may possess proliferative capacity but are unable to establish or
maintain the tumor clone upon serial passage (Clarke et al.,
2006). The T-IC/L-IC terms can also be applied in situations
where a bona-fide CSC exists, but the proper combination of
cell surface markers required for their prospective isolation has
not been found. For ease of reading, we have adopted the
term T-IC/L-IC throughout our review to refer to all cells with
clonal long-term tumor initiating function and not just to those
where prospective isolation has been possible.
Historical Perspectives on Tumor Heterogeneity
Heterogeneity in the cellular morphology of tumors was noted by
the great experimental pathologists of the 1800s. Aside from
cellular morphology and tumor histology (Heppner, 1984),
improved technology has uncovered additional features of het-
erogeneity between tumors, including variation in cell surface
markers (Dexter et al., 1978; Pertschuk et al., 1978; Poste
et al., 1980; Raz et al., 1980), genetic abnormalities (Mitelman
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1980; Dexter et al., 1978; Gray and Pierce, 1964), and response
to therapy (Barranco et al., 1972; Heppner et al., 1978). Early
evidence pointed to the existence of multiple tumor cell subpop-
ulations within single cancers, including melanoma (Gray and
Pierce, 1964), sarcoma (Mitelman, 1971; Prehn, 1970), mam-
mary tumors (Dexter et al., 1978; Henderson and Rous, 1962;
Heppner et al., 1978), colon cancer (Dexter et al., 1979), and
other solid tumors (Klein and Klein, 1956). Along the same lines,
when single cells were cloned from a metastatic mouse mela-
noma cell line and injected into syngeneic hosts, the degree of
metastasis varied extensively, indicating that diversity existed
within the parental tumor cells enabling only some clones to
metastasize (Fidler and Kripke, 1977). Important evidence for
diversification of tumor cell characteristics came from studies
in malignant glioma (Shapiro et al., 1981), where primary human
tumor cells were isolated and mitoses analyzed by karyotyping.
The established karyotypic heterogeneity in the primary tumor
was used as a marker for clonal subpopulations derived from
primary cells through limiting dilution plating. Cloned subpopula-
tions differed with respect to their sensitivity to chemotherapeu-
tics (Yung et al., 1982) and genetic stability (Shapiro et al., 1981).
Evidence that functional tumor cell heterogeneity exists in vivo
came directly from human acute myeloid and lymphoblastic leu-
kemia patients, where in vivo 3H-TdR radiolabeling showed
marked differences in the proliferation kinetics of individual
leukemic cells that could be distinguished on the basis of
morphology (Clarkson et al., 1970; Gavosto et al., 1967; Killmann
et al., 1963). Thus, this era yieldedmany observations describing
variation in functional parameters and established that growth
properties of individual cells within a tumor were far from
homogeneous.
Of particular importance from this earlier era of cancer
research was quantitative evidence from syngeneic mouse tu-
mor grafting experiments showing that the capacity to initiate a
new tumor and sustain disease was variable, with not every
cell able to function as a T-IC (Bruce and Van Der Gaag, 1963;
Hewitt, 1958). The same observations were made in studies
that were carried out in human patients, where tumors were au-
totransplanted subcutaneously into the same patient (Southam
et al., 1962). These studies not only illustrated that tumor reinitia-
tion was variable, but that even in syngeneic recipients T-ICwere
rare. Collectively, these clonal studies established that tumors
are not a collection of homogeneous cells with equal capacity
for proliferation. Instead, analogous to an intricate ecosystem,
tumors are complex networks where individual cells display a
diverse set of characteristics and function together to support
the growth and maintenance of the tumor as a whole.
Since the original conception of evolutionary reasoning (Dar-
win, 1859), it has become evident that genetic diversity within
a species’ gene pool enhances its ability to survive and adapt
to changing environments over time. Likewise, the stability and
robustness of ecosystems depends on the degree of biodiversity
(Loreau et al., 2001; Tilman et al., 2006). In developmental
biology, different specialized cell types need to exist for the
effective functioning of organs. For example, for the proper func-
tioning of the blood system, hematopoietic stem cells (HSCs)
need to produce a heterogeneous pool of specialized cell types
that differ in structure and function. Heterogeneity even withinthe HSC pool has been described (Cheung et al., 2013; Yama-
moto et al., 2013). Without this diversity, the function of the blood
system would be compromised. While the evolution of species
and biodiversity in ecology are consequences of changes at
the genetic level, diversity in cell function and tissue develop-
ment within an organism are the result of nongenetic, develop-
mental programs.
Genetic Mechanisms as the Source of Tumor
Heterogeneity
A guiding principle in cancer research is that tumor initiation and
progression result from the sequential acquisition of genetic mu-
tations that contribute to subsequent clonal expansions (Nowell,
1976). This view is strongly supported by early studies where ge-
netic mutations were analyzed across different stages of colo-
rectal cancer (Vogelstein et al., 1988). These studies established
that genetic changes cause phenotypic manifestations, a finding
that added significant weight to the idea that cancer develop-
ment follows the rules of Darwinian evolution (Cairns, 1975;
Nowell, 1976). The basic premise of this long-standing idea is
that a cell that is endowed with an advantageous heritable muta-
tion generates progeny that has a survival advantage over other
cells that lack this mutation. Consequently, the progeny of the
cell with increased fitness will flourish and produce a clonal pop-
ulation that dominates the site where it originated. Over time,
additional advantageous mutations can arise, endowing a
further growth advantage to another cell within the clone. As
unique subclones arise, different outcomes are possible: less
fit subclones can be completely lost with the most fit subclone
dominating, or many minor subclones can persist alongside
the dominant clone, forming reservoirs from which evolution
can continue. Overall, models where subclones persist and/or
contribute to independent phylogenetic lineage trees within
single tumors are highly reminiscent of the branching evolution
that Darwin described as leading to increased fitness and overall
robustness of a species (Figure 2).
Technological advances have made high-throughput se-
quencing of tumor genomes possible. The last 6 years have
seen a flood of whole exome sequencing (WES) and whole
genome sequencing (WGS) of thousands of tumors, enabling
complex analyses of the mutations that are present within a
single tumor and across multiple tumors (Garraway and Lander,
2013). Several principles are emerging from this work, including
that fact that the mutational burden is highly variable across
tumor types (Lawrence et al., 2013). For example, leukemias
tend to have the lowest number of mutations per tumor
compared to adult solid tumors. Even within the same tumor
type, there is considerable variation in driver mutations and the
same driver mutations can occur in different tumor types, sug-
gesting that the same pathways can be active in different tumors
(Alexandrov et al., 2013; Kandoth et al., 2013). The high intertu-
mor and intratumor heterogeneity makes it difficult to establish
without functional testing whether a particular somatic polymor-
phism is a driver mutation or a passenger variant. WGS shows
that tumors contain thousands of variants, making resolution of
the passenger and driver issue a substantial challenge. The
origin of passenger mutations was recently elegantly docu-
mented in acute myeloid leukemia (AML) genetic studies. Of
the many hundreds of mutations that are found in AML blasts,Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 277
Figure 2. Unified Model of Clonal Evolution and Cancer Stem Cells
Top panel shows that acquisition of favorable mutations can result in clonal
expansion of the founder cell. In parallel, another cell may gain a different
mutation that allows it to form a new subclone. Over time, genetic mutations
accumulate and subclones evolve in parallel. Bottom panel shows that it may
be that CSCs are not static entities but can evolve over the lifetime of a cancer
as genetic changes can influence CSC frequency. Some subclones may
contain a steep developmental hierarchy (left), where only few self-renewing
CSCs exist among a large number of non-CSCs.Other subclones (middle) may
contain an intermediate hierarchy, where the number of CSCs is relatively high
but a hierarchy still exists. Some subclones may have the genetic alterations
that confer high self-renewal potential, where most cells are tumorigenic. In
this scenario, applying the CSC concept to such homogeneous subclones is
not warranted because most cells can self-renew and few non-CSC progeny
are generated.
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of origin for the AML subclone; these mutations arose every time
the normal HSC divided and remained functionally neutral and
thus can be considered passengers (Jan et al., 2012; Welch
et al., 2012). The acquisition of the oncogenic driver within one
such HSC ‘‘trapped’’ the preexisting spectrum of mutations
within the AML subclone that expanded and progressed from
this initiating cell. After development of leukemia, very few
additional mutations are needed to drive the last population
expansion, although hits continue to be acquired as the disease
progresses (Jan et al., 2012; Welch et al., 2012). Thus, the driver
and cooperating mutations that the AML subclone acquires dur-
ing leukemic progression need to be filtered out from the large
spectrum of passengers that preexisted and will continue to
arise as AML cells proliferate. Similar approaches have been
taken in breast cancer and other solid tumors to distinguish
drivers from passengers (Nik-Zainal et al., 2012; Stephens
et al., 2012). While these approaches clearly document how
the mutational landscape of individual patients can influence
the heterogeneous properties between patients, more sophisti-
cated approaches are needed to determine how genetic mech-
anisms contribute to heterogeneity within tumors.
Intratumoral Genetic Diversity
A key proposition of the multistep tumorigenesis model put forth
by Cairns and Nowell is that there are sequential sweeps of
clonal dominance that are variably detected depending on
when a tumor is sampled. However, they also conceived that
the tumor might contain multiple branches or subclones that
are evolving independently (Figure 2). Indeed, with deeper
sequencing and improved bioinformatic methods, it is becoming278 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.clear that tumors are often composed of a dominant genetic
clone plus one or more genetically distinct subclones. For
example, topological sampling of tumors has shown that
different regions possess distinct mutations that are reflective
of genetic subclones seeding different parts of a single tumor
(Gerlinger et al., 2012). In the case of metastatic renal cancer,
70% of somatic variants were not found in all biopsies of the
same tumor; only a VHL mutation and loss of a region on 3p
were ubiquitous. Even gene-expression signatures of good
and poor prognosis were detected in different regions of the
same tumor. Intratumoral diversity with respect to metastatic
progression was shown in pancreatic cancer. By sequencing
the genomes ofmetastases and different regions ofmatched pri-
mary tumors obtained through rapid autopsies from seven indi-
viduals with end stage pancreatic cancer, the primary tumor was
found to harbor geographically and genetically distinct sub-
clones that gave rise to lung, liver, or peritoneal metastases
within the same patient (Yachida et al., 2010). Importantly,
despite the presence of founder mutations within the parental
clones, the cells giving rise to metastatic lesions had a large
number of additional mutations, indicating that further clonal
evolution had taken place during metastasis. Others have also
reported genetic heterogeneity between metastasis-initiating
cells in pancreatic cancer (Campbell et al., 2010). These studies
highlight the complexity in predicting which subclones will prog-
ress to metastasis, even after the genomic architecture of the
primary tumor is established.
With the ability to detect genetic subclones within tumors, it is
now possible to create lineage maps that provide insight into the
subclonal evolution. Such advancements have made it possible
to reconstruct the life histories of breast cancers (Nik-Zainal
et al., 2012). By sequencing 20 breast cancers to an average
30–403 coverage and one cancer to 1883 depth and applying
a new bioinformatics algorithm (Greenman et al., 2012) to recon-
struct the genomic history, the authors showed that breast can-
cer evolves through acquisition of driver mutations that produce
clonal expansions. Interestingly, the drivermutations occur infre-
quently in long-lived lineages that passively accumulate muta-
tions without expansions. The most recent common ancestor
appeared surprisingly early, indicating that much of the time is
spent driving subclonal diversification and evolution among the
nascent cancer cells (Nik-Zainal et al., 2012). These studies do
not just give a snapshot of the tumor, but narrate the steps it
has taken before it was diagnosed, providing promising avenues
for earlier screening. One caveat of these studies is that interpa-
tient tumor genetic variability is likely extensive and it may thus
be challenging to delineate a common set of steps that are char-
acteristic of different breast cancer subtypes. The key question
that the discovery of subclonal diversity raises is which clones
will survive therapy and progress to cause recurrence and/or
metastasis.
Studies in leukemia have been particularly instructive in
revealing the presence of subclones and their role in tumor pro-
gression. Analysis of chromosomal translocation breakpoints
and DNA copy-number alteration (CNA) profiling in twins with
ETV6-RUNX1 positive acute lymphoblastic leukemia (ALL)
showed that a preleukemic clone is initiated in utero that ex-
pands, seeds both twins, but then evolves with different kinetics
and CNA acquisition in each twin (Bateman et al., 2010; Hong
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profiling of paired diagnostic and relapse samples of ALL has
been informative (Inaba et al., 2013; Mullighan et al., 2008). In
approximately 40% of cases, the leukemic subclone present at
relapse was identical to the subclone present at diagnosis or it
was a direct evolutionary product. However in 50% of cases,
the relapse subclone shared only limited genetic identity with
the diagnostic subclone and did not evolve from it. Similar find-
ings came from WGS studies of paired diagnosis and relapse
AML samples: the major population at relapse shared only
limited genetic identity with the major population at diagnosis
and did not evolve from it. These findings from B-ALL and AML
predicted the presence of genetically distinct subclones at diag-
nosis and the existence of ancestral, prediagnostic subclones.
These results indicate that tumor evolution may occur through
a more complex branching model that gives rise to genetically
distinct subclones at diagnosis that vary in aggressiveness and
response to therapy (Greaves, 2009, 2010). Moreover, these
data establish that there is subclonal variation in both the
response to therapy and the probability that a subclone will sur-
vive and regenerate a new tumor.
However, these are still in silico depictions of intratumoral di-
versity and they are inferred from bulk tumor tissue. This limita-
tion makes it difficult to determine how and when population
expansions occurred to generate subclones and there are ques-
tions of whether the sequencing was deep enough to reveal the
entire population substructure. Like population studies of human
evolution or in ecology, lineage trees that describe evolutionary
history are best undertaken with single cells. If large numbers
of single cells are analyzed, their relationship to one another
can be mapped and phylogenetic lineage trees can be created
(Melchor et al., 2014; Navin et al., 2011; Potter et al., 2013;
Shlush et al., 2012). Early studies of this type have now been re-
ported for some leukemias and lymphomas, and they reveal a
high degree of complexity within single tumors. Shlush et al.
tracked polymorphic somatic mutations in large numbers of sin-
gle leukemia cells taken at diagnosis and relapse and recon-
structed cell lineage trees based on their divisional history. The
reconstructed lineage trees from cells at relapse were shallow
(indicating that they divide rarely) compared to cells at diagnosis,
which showedmanymore subpopulations. Interestingly, relapse
cells were closely related to the L-IC enriched subpopulation
from the diagnostic sample, which is known to be relatively
quiescent. This result implies that in these instances, relapse
might have originated from rarely dividing L-IC. Given the impor-
tance of L-ICs to tumor growth, it will be important to broaden
this type of single cell analysis tomore samples and to determine
the extent to which L-IC are involved in establishing a genetically
diverse relapse.
Collectively, the identification of genetically diverse subclones
within single tumors provides strong evidence that intratumoral
heterogeneity can be driven by the unique mutation spectrum
present within each subclone (Figure 1). However, key questions
remain that sequencing studies alone cannot resolve. One major
challenge is determining which mutations are able to drive tumor
growth and how to link these drivers to the clonal propagation
potential of subclones. Does genetic diversity exist in tumor cells
that are responsible for long-term tumor propagation? Which
subclones will evolve further? Will all cells within a subclone beequally sensitive to therapy? Which clones will recur or metasta-
size? Studies to answer these questions require functional
assays.
Nongenetic Mechanisms as the Source of
Heterogeneity—the Cancer Stem Cell Model
Although the idea that cancer retains features of embryological
development has a long history (Cohnheim, 1875), the modern
idea that developmental programs underlying normal tissue
organization may still function to some extent in cancer began
with seminal studies of teratocarcinoma (Pierce et al., 1960),
small cell lung carcinoma (Baylin et al., 1978), andmammary car-
cinoma (Bennett et al., 1978; Hager et al., 1981). They suggested
that many tumor cells were differentiated and that these ‘‘differ-
entiated’’ cells were generated by tumor ‘‘stem’’ cells, similar to
normal tissue stem cells producing normally differentiated tis-
sues. Thus, tumors can be considered as caricatures of embryo-
genesis or normal tissue renewal (Pierce and Cox, 1978; Pierce
and Speers, 1988). Early studies in the hematopoietic system
were also instructive. There was clear evidence from cytokinetic
labeling studies that themajority of leukemia blasts were postmi-
totic and needed to be replenished from a small population of
highly proliferative cells (Clarkson et al., 1967; Clarkson et al.,
1965; Clarkson, 1969). Presciently, these studies also predicted
the existence of a rare leukemic population that cycled very
slowly and showed resistance to antiproliferative therapies and
therefore was thought be the source of recurrence. Since similar
cytokinetics were observed for normal hematopoietic stem cells,
it was proposed that the slow-cycling leukemia cells were
responsible for the continued generation of the proliferative frac-
tion, representing a leukemic ‘‘stem cell’’ population (Clarkson,
1974). These early studies, together with efforts to identify clono-
genic AML progenitors (Buick et al., 1977; McCulloch, 1983;
Metcalf et al., 1969; Moore et al., 1973), sparked an interest in
thinking about leukemia in terms of hierarchical organization,
as was being established for normal hematopoiesis at that time.
In order to demonstrate that a tumor is organized in a hierar-
chical manner, it is crucial to establish that it consists of function-
ally distinct cell types that can be prospectively purified and
assayed. With the development of fluorescence-activated cell
sorting techniques (Bonner et al., 1972), coupled with refine-
ments in xenografting techniques in immune-deficient mice, it
was possible to engraft normal human hematopoietic cells
(Kamel-Reid and Dick, 1988; Lapidot et al., 1992) and leukemic
cells in mice (Dick et al., 1991; Kamel-Reid et al., 1991; Kamel-
Reid et al., 1989). These tools, along with quantitative assays,
set the stage for the first purification of T-IC, the operational
term for human CSCs (Clarke et al., 2006).
Flow sorting using cell surface markers CD34 and CD38 was
used to prospectively isolate human T-IC in AML, termed leuke-
mia-initiating cells (L-IC) (Lapidot et al., 1994). The leukemia
initiation potential was in the CD34+CD38 fraction and no
engraftment was detected from the CD34+CD38+ or CD34 frac-
tions. By injecting different numbers of cells per mouse and
establishing a linear correlation with engraftment, it was calcu-
lated that 1 in 2.53 105 cells could initiate a leukemic graft (Lap-
idot et al., 1994). Analysis of additional AML samples in a more
sensitive immune-deficient mouse model (using non-obese dia-
betic/severe combined immunodeficiency [NOD/SCID] mice)Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 279
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lishing that AML is organized as a hierarchy with CD34+CD38
L-IC at the apex. These studies provided proof for the
hypotheses from the 1960s and established that not every
AML cell was equal and only rare cells were L-IC.
The initial studies in AML laid the foundation for the generation
of CSC studies in solid tumors that followed. The first identifica-
tion of CSCs in a solid tumor was achieved over ten years ago in
human breast cancer (Al-Hajj et al., 2003). A subset of breast
cancer cells (CD44+CD24) was prospectively isolated and
shown to be solely responsible for sustaining the disease in
immune-deficient mice. The CSC subset could be serially
passaged and the xenografts generated were histologically het-
erogeneous, resembling the parent tumor from which they were
derived. These results demonstrated that the same CSC princi-
ples that had previously been shown to apply in an AML model
could also be translated to a solid tumor. Since the initial publi-
cation in breast cancer, a plethora of papers have been pub-
lished identifying CSCs in numerous cancers including brain
(Singh et al., 2004), head and neck (Prince et al., 2007), pancreas
(Hermann et al., 2007; Li et al., 2007), lung (Eramo et al., 2008),
prostate (Collins et al., 2005; Patrawala et al., 2006), colon
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007), and sarcoma
(Wu et al., 2007). In all cases, non-T-ICs were generated in the
xenografts providing evidence for hierarchical organization.
However, in most cases where patient-derived cancer samples
were used, no genetic analysis was undertaken to compare
the xenografts to the primary tumor to determine whether there
was selective outgrowth of one or more subclones. Nonetheless,
CSCs appeared to be a common feature across different cancer
subtypes and tumors from different tissues. Collectively, the
studies illustrated that the ability to initiate and propagate tumor
growth varies between different cells within a cancer and that
this variation is due to a hierarchical relationship between tumor-
igenic and nontumorigenic cells. This relationship is comparable
to developmental hierarchies seen in normal tissues where stem
cells reside at the apex and are responsible for generating
progeny that in turn exhibit increasing commitment and lineage
restriction.
Xenografting and CSC Detection
Because tumor initiation is one of the defining features of CSCs,
xenografting is central to the CSC model. A limitation of xeno-
graft studies is that even orthotopic transplantation may not
faithfully reproduce the TME or the growth factor milieu found
within a patient’s tumor. Some murine growth factors are not
cross-species reactive (e.g., TNF) (Bossen et al., 2006; Rong-
vaux et al., 2013). These environmental differences can impart
selective forces on tumor cells. As a result, some cells that
would possess T-IC activity in humans might not display growth
as xenografts. Moreover, the experimental techniques neces-
sary to obtain single cells to test for T-IC activity are harsh.
Digestion of a solid tumor into single cells causes a loss of
stromal components and cellular architecture. Cells are under
atmospheric oxygen levels and are subjected to abrupt changes
in nutrients and pH. Furthermore, cells are stained with anti-
bodies to cell-surface molecules and passed through a sorting
machine to separate putative CSCs from non-CSCs. After hours
of preparation under conditions that are drastically different280 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.from the native environment of the tumor, cells are then finally
injected back into a xenogeneic environment and assayed for
growth potential. Given these harsh experimental procedures,
testing for the presence of CSCs effectively tests for the most
robust cell that can grow. In addition, key aspects of the TME
are altered in the transplantation process. All of these changes
may affect a cancer cell’s growth properties in the xenograft
assay.
Over the past two decades, there have been steady improve-
ments to the xenograft assay, including development of more
immune-deficient recipient mice, better methods for transplan-
tation, and humanizing recipients with human TME and/or
growth factors (Rongvaux et al., 2013). Accordingly, some
aspects of the initial CSC model have needed to be refined.
For example, L-ICs were thought to reside solely in the
CD34+CD38 fraction of AML (Bonnet and Dick, 1997; Lapidot
et al., 1994). However, by using more immune-deficient
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, L-IC can now
be detected in other fractions (Taussig et al., 2008). Careful ex-
amination of larger sample numbers using NSG mice together
with intrafemoral transplantation to improve the sensitivity for
L-IC detection has confirmed the essential conclusion of the
original studies: in virtually all samples, L-IC reside in the
CD34+CD38 fraction. Still, in at least half of the samples
(>100 samples tested, data not shown), L-ICs are also found in
at least one other fraction (usually CD34+CD38+). In addition to
analyzing the phenotypic fractions that contain L-ICs, the size
of the population and the L-IC frequency therein need to be taken
into account. Nevertheless, in the vast majority of cases evi-
dence of a hierarchy is still seen since fractions devoid of L-IC
are found (Eppert et al., 2011). In those samples where cell
surface marker analysis using CD34 and CD38 cannot identify
a cell fraction that is devoid of L-IC activity, we have found that
sorting cells on the basis of miRNA expression levels can be
used to prospectively separate L-IC and non-L-IC fractions
(Gentner et al., 2010; Lechman et al., 2012). Thus, even in those
samples we cannot conclude a priori that the tumor does not
follow the CSC model. Rather, we suggest that the cell surface
markers are uninformative and not valid to make a determination
of hierarchical organization in those cases. The use of sorting
based on differential expression of miRNA represents a poten-
tially powerful method that has already shown utility for sorting
human HSC. This method needs to be explored further as a
means to fractionate cells when cell surface markers are not
available (as for many solid tumor types) or where they are unin-
formative (Amendola et al., 2013). In addition to miRNA, the use
of reporter assays that measure cellular signaling pathway activ-
ity, such as the Wnt reporter (Vermeulen et al., 2010), can be
used as alternative means of measuring distinct cellular fractions
that may segregate T-IC and non-T-IC. The tools for analyses of
other important pathways in human cells is only beginning to
emerge and it will be interesting to see how intracellular signaling
markers will impact the identification of T-ICs. At least in AML,
the strongest independent piece of evidence supporting the
utility of the xenograft assay to detect bona fide L-IC is that
only gene signatures from functionally validated L-IC popula-
tions are strongly prognostic for patient survival (Eppert et al.,
2011). This and other evidence is presented in the Linking Stem-
ness, Prognosis, and Therapy section.
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discordant findings regarding the phenotype and properties of
T-IC depending on experimental conditions and the type of
xenograft assays employed. Through the use of recipients with
increased immune-deficiency, the assayed frequency of T-IC
in melanoma changed by many orders of magnitude such that
the most permissive recipient read out a T-IC frequency of virtu-
ally 1 in 1 (Quintana et al., 2010). As most tumor cells were T-IC,
such tumors appear to be homogeneous and not following a
hierarchical model of tumor organization, although some have
argued that there may be methodological explanations (Boiko
et al., 2010). Nevertheless, use of more immune-deficient mouse
models does not necessarily change the evidence documenting
the existence of CSC and formany tumors a hierarchy containing
T-IC and non-T-IC was seen (Ishizawa et al., 2010; O’Brien et al.,
2012). In others cases such as breast cancer, the implantation of
human stromal elements appears to mitigate many problems
and enables reliable detection of T-IC (Kuperwasser et al.,
2004). Overall, future use of recipients that express components
of the human immune system, as well as cross-species reactive
growth factors, should be valuable modifications to the xeno-
graft assay and enable more reliable evaluation of hierarchical
organization in tumors.
Given the central importance of the xenograft assay to mea-
sure functional cancer cell properties and its heavy use in CSC
research and experimental drug studies, it is important to fully
describe the characteristics, including the genetic make-up, of
cancers that grow as xenografts. A major limitation of CSC
studies to date is that there has been a lack of integration of
genomic and functional properties of T-ICs as we describe later
in this Review. Notably, it remains to be determined which
genetic clones can generate grafts in mice and how this
influences the corresponding CSC measurements.
Clonal Dynamics, Dormancy, and Therapy Failure
Although the studies described above indicate that not all tumor
cells possess T-IC function, anothermajor question is whether all
T-IC are equal in their tumor propagation ability. If there is varia-
tion, it will be important to establish whether the variation exists
within cells of a single genetic clone. The answer to this question
holds major importance to the design of future cancer therapeu-
tics. Addressing this question requires genetic analyses com-
bined with functional assays that measure tumor propagation
at the resolution of individual clones. We have recently charac-
terized colon cancer xenografts and shown that single genetic
subclones from the patient tumor can be separated and stably
propagated over multiple passages in mice. Being able to prop-
agate a genetic clone allowed us to track the behavior of cells
within unigenetic lineages. By using lentivirus-mediated cell
marking, we mapped the growth dynamics of 150 marked cells
from ten primary human colon cancer samples in serial trans-
plants that spanned 387 days of tumor growth on average (Kreso
et al., 2013). In every genetic clone that we analyzed, we de-
tected significant variation of cellular behaviors: some marked
cells were proliferative and persisted at every transplant,
whereas others were less robust and could not be detected at
later points during transplantation. Thus, these results directly
identify functional diversity among cells that are part of a single
genetic clone in a solid tumor.In addition, approximately 20% of marked cells were initially
undetectable, but following serial transplantation such cells
became activated and continued to function (Kreso et al.,
2013). This provided formal evidence for the existence of
dormant cell populations that drive tumor growth in primary
human colon cancer. Moreover, by treating xenografts with con-
ventional chemotherapy, we discovered that while some long-
term persisting cells were eradicated, the dormant cells survived
treatment and contributed to tumor regrowth. These changes
were not accompanied by selection of distinct genetic sub-
clones, as the control and treated tumors displayed close ge-
netic identity. Tumor cell dormancy has been observed in other
systems, including breast cancer, melanoma, and leukemia
(Pece et al., 2010; Roesch et al., 2010; Saito et al., 2010).
Because most conventional chemotherapies are largely cyto-
toxic to dividing cells, dormancy may provide cells with a means
of escape or survival (Figure 3), although other mechanisms,
such as acquisition of new mutations or selection of cells with
preexisting genetic mutations, could also be at work to ensure
survival following therapy. Collectively, these studies provide
evidence that even within a single genetic clone, cancer cells
are heterogeneous in their ability to survive chemotherapeutic
insults. This added layer of functional diversity adds a new tier
of complexity within tumors.
Plasticity and CSC Detection
In vitro studies have often been used as surrogate means of
studying T-IC. A number of reports using cell lines that have
been cultured in vitro have shown that the T-IC state is not static.
Sorted T-IC enriched populations generated non-T-IC, but some
studies found that sorted non-T-IC populations could generate
T-IC (Gupta et al., 2011; Magee et al., 2012; Sharma et al.,
2010). Studies of JARID1B, a histone demethylase, have been
informative and highlight the complexity of the T-IC state in mel-
anomas. JARID1B was shown to mark slowly cycling melanoma
cells that are essential for continuous tumor growth of estab-
lished melanomas and metastatic progression, but are not
required for tumor initiation (Roesch et al., 2010). JARID1B
expression was limited to a small subpopulation of melanoma
cells, but the maintenance of this subpopulation was dynamic:
while purified JARID1B-positive cells generated JARID1B-nega-
tive cells, as expected by the CSCmodel, single JARID1B-nega-
tive cells also gave rise to heterogeneous progeny, including
JARID1B-positive cells. This study indicates that some cells
that are essential for tumor maintenance may not be static
entities, but rather can acquire tumor maintenance capabilities
depending on the context.
The finding that normal stem cells can reenter the stem cell
state (Mani et al., 2008) gave way to the idea that it may be
possible to generate T-IC from non-T-IC under some conditions.
Indeed, EMT factors have been used to generate T-IC from non-
T-IC in breast cancer (Chaffer et al., 2013). The environment in
which tumor cells reside can also induce stem-like states in can-
cer cells. For example, myofibroblast-secreted factors, including
hepatocyte growth factor, can induce Wnt signaling in colon
cancer cells and consequently induce a T-IC-like state in more
differentiated tumor cells in vivo (Vermeulen et al., 2010). In
mouse models of intestinal tumor initiation, epithelial nonstem
cells can reexpress stem cell markers upon Wnt activation andCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 281
Figure 3. Functional Diversity between Cells within Subclones
Impacts Response to Therapy
Each clone (depicted by the different colors) contains a mixture of cells that
vary with respect to their stemness and/or proliferative ability, including rela-
tively dormant cells. Together these factors represent the functional diversity
present within single genetic subclones. Chemotherapy can reduce tumor
burden by eliminating the highly proliferative cells within subclones, while
sparing the relatively dormant cells; following therapy, these cells can seed a
new cancer. Thereby, subclonal diversity can be altered with chemotherapy
and can allow for the selection of cells with additional genetic mutations that
confer a survival advantage. Not depicted in the diagram is the concept that
chemotherapy-resistant cells can exist before treatment and can be selected
following chemotherapy. Thus, chemotherapy can introduce newmutations to
confer treatment resistance, but it can also select preexisting cells that
accumulated mutations, which confer chemotherapy resistance during the
long evolution of the tumor before it was diagnosed.
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perivascular nitric oxide that is released by endothelial cells can
activate Notch signaling and induce a stem-like state in PDGF-
induced gliomas (Charles et al., 2010). These studies highlight
the dynamic nature of cancer cells and show the importance of
the stem cell state in tumor generation.
Given the importance of these concepts, it will be important to
show whether other cancers possess such properties. As well, it
will be critical to determine to what extent plasticity exists in pri-
mary tumor tissue, as opposed to cell lines, and whether it is282 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.induced in vivo. Although provocative, some studies reporting
plasticity were not done clonally and this is essential to under-
stand the homogeneity of cells in each state and the frequency
of cells that are able to change states. Is every non-T-IC able
to generate a new T-IC, or are only some non-T-ICs responsible
for the generation of new T-IC? If only some, does this reflect
heterogeneity of the non-T-IC population? Clearly tumors with
a high probability of interconversion between T-IC and non-
T-IC states render hierarchical cellular organization less mean-
ingful than if such interconversions are rare. Normal tissue
stem cells can also ‘‘dedifferentiate’’ into a more primitive state
when normal tissue homeostasis is perturbed, for example dur-
ing transplantation procedures or following stem cell ablation
(Rinkevich et al., 2011; Tata et al., 2013; Van Keymeulen et al.,
2011). Thus, it will be important to determine the probability of
being in one state versus another and the factors that influence
such interconversions (Gupta et al., 2009). However, even in
tumors where the interconversion rate is high, the available
data indicates that when a cancer cell possesses stemness
properties it is more likely to progress, metastasize, resist ther-
apy, and self-renew, compared towhen it is in the opposite state.
Thus, even for tumors that do not strictly follow the CSC model,
the concept that stemness is an important aspect of the biology
of that cell remains strong. As such, novel approaches will be
needed to eradicate cells that display determinants of stemness.
Epigenetics and Stemness
The primary, nonmutational mechanism that governs develop-
mental hierarchies is epigenetic regulation of the genome. Epige-
netic modifications of DNA, histones, and nucleosomes as well
as noncoding RNAs, including miRNA, allow for modification of
gene expression (Baylin and Jones, 2011; Iorio and Croce,
2012). Alterations in the epigenome dictate cell fate specification
and have been used as means of reprogramming noncancerous
cells. Although epigenetic modifications are not as stable as
mutational changes and can be reversed, some types of modifi-
cation are a stable, heritable means by which distinct cellular
states and functions can be generated. The importance of epige-
netic regulation in generating diversity apart from genetic muta-
tion has been shown in several systems. For example, a small
proportion of slowly cycling melanoma cells that are essential
for tumor growth can be purified based on the expression of
JARID1B, amember of the jumonji/ARID1 histone 3 K4 demethy-
lases (Roesch et al., 2010). Other epigenetic factors including
members of the Polycomb group of transcriptional repressors
(BMI-1 and EZH2) that are linked to normal stem cell self-renewal
have been shown to exhibit variation in expression levels within
tumors and play a role in tumor progression (Sparmann and van
Lohuizen, 2006). Further support for the role of stemness in can-
cer biology is emerging from cancer genome-sequencing efforts
showing that genetic disruption of epigenetic regulators of
normal stem cell function is critical for cancer pathogenesis.
Mutation in DNMT3A, which is highly recurrent in AML, causes
major dysregulation of gene expression leading to upregulation
of stemness genes and increased repopulation and self-renewal
of normal HSC (Ley et al., 2010; Shah and Licht, 2011).
Other highly recurrent mutations in genes such as IDH1/IDH2
and TET2 affect epigenetic programs that underlie stemness
for many cancers, including AML (Abdel-Wahab and Levine,
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normal cell diversification, are becoming increasingly relevant
for the maintenance of different cancer cell states.
Epigenetic mechanisms can also be important for the ob-
served variability in response to therapy (Glasspool et al.,
2006). A small population of cells that remain drug-tolerant
following treatment has been reported across several cell lines,
including cells derived from melanoma, lung, gastric, colon,
and breast cancers (Sharma et al., 2010). Following treatment
of these drug-sensitive cell lines with anticancer agents, the
authors observed a small proportion of cells that persist, remain-
ing viable while the majority of cells are killed by the therapy.
This drug-tolerant phenotype was related to changes at the
level of global chromatin, with high expression of the histone
demethylase JARID1A and IGF-1R signaling in drug tolerant
cells (Sharma et al., 2010). Importantly, heterogeneity in drug
response can be generated even when cultures are initiated
from single cancer cells, indicating a nongenetic mechanism.
Others have found that escape of cells from anticancer drug
treatment involves a survival advantage conferred by cell-to-
cell variability in the dynamics of specific proteins (Cohen
et al., 2008). Substantial variation between daughter cells in
response to antimitotic drugs has also been reported that is
not the result of genetic differences, but rather due to competing
intracellular networks involving caspase activation and cyclin B1
levels (Gascoigne and Taylor, 2008). Overall, these studies high-
light the importance of nongenetic mechanisms governing both
cellular fates and drug response. It will be important to discern
how these in vitro studies translate to in vivo growth properties
of cancer cells following drug administration.
Gene-expression analysis is another important means by
which different cellular states can be identified. By using single
cell multiplex PCR analysis in combination with fluorescence-
activated cell sorting, it has been shown that colon tumors
contain subpopulations of cells whose transcriptional states
mirror those of the lineages found in the normal colon epithe-
lium (Dalerba et al., 2011). Importantly, these authors show
that a tumor derived from a single cell can exhibit the morpho-
logical diversity and transcriptional variability reflective of
multilineage differentiation seen in normal colon tissue. These
gene-expression programs are also important indicators of
patient survival (Dalerba et al., 2011), formally proving that
epigenetic heterogeneity due to multilineage differentiation
processes can establish phenotypic and functional diversity in
tumor clones. As such, it is evident that tumor heterogeneity
can arise due to transcriptional programs that are reminiscent
of normal tissue differentiation, which are independent of
genetic diversity.
Noisy Gene Expression and Heterogeneity
Studies in lower organisms have found that stochastic nonge-
netic processes involving protein production or degradation
can account for numerous phenotypic effects (Losick and Des-
plan, 2008; Su¨el et al., 2007; Wernet et al., 2006). In mammalian
cells, survival of apparently homogeneous cells can be dictated
by natural differences in protein levels, which regulate receptor-
mediated apoptosis between cells and illustrate the dramatic
effects that noise in gene expression can have (Spencer et al.,
2009). The variability in levels of proteins within cells, albeittransiently heritable, quickly changes in daughter cells due to
different growth rates and noise in gene expression. As such,
it is inherently different from epigenetic regulation discussed
above. Nonetheless, the variability between cells with respect
to noise in gene expression and variability in signal transduction
components has implications for tumor biology and therapeu-
tics. Traditionally, the failure of a therapy to eradicate all cells
has been ascribed to genetic differences, proliferative status,
or the microenvironment, but it is possible that the variability of
cells to respond can also be governed by natural differences in
protein levels.
At the level of cell populations, evidence is emerging to sup-
port stochastic processes governing cell state equilibriums.
For example, breast cancer cell lines, separated into different
phenotypic fractions or ‘‘states’’ based on cell surface marker
expression, return to equilibrium proportions over time in vitro.
This progression toward equilibrium proportions was the result
of interconversion between different phenotypic states, which
can be modeled as stochastic processes that occur with each
cell division using the Markov process, where interconversion
rates depend only on the cell’s current state (Gupta et al.,
2011). This study provided a theoretical framework for explaining
phenotypic equilibriums in breast cancer cell lines. It will be
important to see these principles established in primary cancers
where T-IC can be highly resolved by sorting and tested in robust
clonal serial T-IC assays.
Collectively, these studies indicate that in apparently homoge-
neous environments, cells of the same genotype can exist in
different states that influence their behavior. The implications
of such variability to biology and medicine are important. The
implicit assumption most experimental studies take is that a uni-
form cell population reacts in a uniform manner. However, given
the biological noise between individual cells, the effects of treat-
ments on populations are likely underestimated, as averaging
data across many cells can have the net effect of masking
heterogeneity at the single cell level. With new technological
advances, an increasing number of single-cell studies are being
reported that demonstrate considerable cell-to-cell variability in
apparently homogeneous populations. For example, quantita-
tive PCR gene-expression analysis of 280 geneswas undertaken
for 1,500 single cells that span a variety of highly purified mouse
HSC and progenitor populations. This study uncovered a large
degree of heterogeneity within cell types that were classically
thought to represent a uniform collection of cells (Guo et al.,
2013). It will be important to establish whether such variation is
the result of technical variability in the assays used, or whether
it represents true differences in biological function. In the context
of the CSC model, extensive cellular variability within what is
thought to be a uniform CSC population has implications for
therapeutic targeting. Therapy directed against a molecular
target might not be effective if intrinsic variability in the cellular
context renders subsets of cells within the population unequally
responsive to drug targeting.
Limitations of Genetic and Nongenetic Models
As we have argued throughout this Review, both genetic and
nongenetic determinants influence tumor heterogeneity and
often these two views have been presented as mutually exclu-
sive models, stimulating intense debate (Clevers, 2011; MarusykCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 283
Figure 4. Failure to Separate Genetic
Subclones May Confound Conclusions
Regarding Source of Cancer Heterogeneity
Left panel shows that if cancer cells are not
separated into distinct genetic subclones before
they are tested for the presence of a hierarchical
organization, then T-IC measurement may not
reflect the complexity of the parental cancer. Right
panel shows that cells from the purple clone have a
high number of engrafting cells irrespective of a
marker that is used to prospectively purify T-ICs.
On the contrary, T-ICs can be prospectively puri-
fied from the green clone. Of note, the clones de-
picted in yellow and blue contain T-IC but in this
example they are not positive for the marker of
choice. This highlights that multiple markers may
be required to identify T-ICs from distinct genetic
subclones.
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isolation is insufficient to explain fully the diversity seen within
cancers. The genetic model focuses on genetic heterogeneity
without considering that individual cells within a genetically
homogeneous subclone might still exhibit variation in function
due to any of the nongenetic determinants described above.
Similarly, a major limitation of the CSC model or hierarchical
model is that it views the tumor as being genetically homoge-
neous and static, without accounting for the existence of
genetically distinct subclones or tumor evolution. For example,
a tumor might contain different subclones, some of which
are virtually homogeneous in terms of T-IC activity because
they are highly progressed and possess a high mutational
burden, whereas other subclones with fewer oncogenic muta-
tions might be almost devoid of T-IC. Such subclones could
also possess differences in the cell surface markers used for
sorting. Thus fractionation of the bulk tumor into T-IC and
non-T-IC populations could simply be the result of segre-
gating subclones with very low T-IC activity from those with
high T-IC activity (Figure 4). In this scenario, sorting has simply
segregated on the basis of genetic identity rather than
providing the essential test of the CSC model, which requires
testing the T-IC ability of genetically identical cells within a
single subclone (Figure 5), as described recently in our
study of the clonal dynamics of T-IC from human colon cancer
(Kreso et al., 2013). Clearly the recent findings on subclonal
diversity raise an important challenge to the validity of the
broad literature on T-IC. Despite these concerns, as we will
argue below, we propose that the genetic clonal evolution
and CSC models can be unified into a comprehensive view of
cancer heterogeneity.284 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.Unification of the CSC and Clonal
Evolution Models
From a conceptual standpoint it is clear
that therapy failure and recurrence are
not simply due to the acquisition of new
mutations. Rather, the surviving tumor
cells must also have regenerative poten-
tial in order to regrow the tumor; cells
contributing to recurrence must behave
like T-IC. Further, tumors are dynamic
entities: cells are dying, proliferating, orentering dormancy. Thus, static genetic analysis of bulk tumor
tissue or single-cell topological sampling of different tumor sites
cannot formally prove that any particular genetically distinct cell
or subclone is functionally important. For instance, a laser-
captured cell used for genomic analysis might be on a trajectory
toward death just before it is sampled and therefore is not rele-
vant for tumor growth. Arguably, the only important cells in a
tumor are the ones that are responsible for long-term clonal
growth; any other cell ultimately leads to clonal exhaustion. As
such, clone-propagating cells represent the unit of selection
for the tumor (Greaves, 2013). As we argue above, the hallmark
of such a cell is the capacity to self-renew, as without self-
renewal clonal exhaustion is inevitable. Thus, a critical question
that arises from the many sequencing studies that have
described intra-tumoral subclonal diversity is whether diversity
exists in long term propagating cancer cells. The best way to
test this question is by combining cancer genetic analyses with
functional T-IC assays of primary human cancers.
Three independent studies in human B-ALL and T-ALL have
provided the essential evidence that subclonal genetic diversity
exists within functionally defined L-IC (Anderson et al., 2011;
Clappier et al., 2011; Notta et al., 2011). Elegant single cell
FISH studies established that the diagnostic tumor contained
genetic subclones and provided evidence for the evolutionary
relationship between them. In all three studies, diagnostic sam-
ples were transplanted into xenograft recipients and since only
L-IC are able to initiate leukemic propagation, the genetic
makeup of the xenografts reflected the genotype of the L-IC(s)
that were transplanted. Individual mice transplanted with cells
from the same sample were shown to contain genetically distinct
subclones, proving that genetic diversity exists among L-ICs.
Figure 5. Experimental Approach to
Investigate CSC Properties in the Context of
Genetic Subclones
Studying CSCs will require separation of distinct
genetic subclones, because CSCs cannot be
reliably identified in genetically heterogeneous
tumors. One method by which subclones can be
separated is by transplanting cancer cells at clonal
cell doses over multiple recipients. Following
engraftment of the human cancer cells, the hier-
archical composition of a particular subclone can
be studied using prospective purification of cells.
Sequential transplantations of cancer cells allows
for the tracking of further clonal evolution. For solid
tumors, sampling different geographical regions
from the primary tumor will be important for
capturing distinct subclones. Although not de-
picted, deep sequencing and analyzing different
metastatic sites can be used to analyze the genetic
lineage relationships of subclones within a cancer.
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clone resulted in variability in functional properties including
stemness, L-IC frequency, and aggressiveness of xenograft re-
population. Indeed, some subcloneswith less aggressive growth
properties could only be detected in clonal assays when they
were transplanted at limiting dilution, without competition from
more aggressive subclones. Characterization of subclonal ge-
netic diversity enabled reconstruction of the evolutionary
process reaching back to the ancestral subclone, and demon-
strated that functionally distinct subclones were related by
branching evolution (Notta et al., 2011). Importantly, these
studies showed that some xenografts were repopulated with a
minor diagnostic subclone that was related to a paired relapse
sample (Anderson et al., 2011; Clappier et al., 2011). Collectively,
these xenograft studies provided functional proof for the predic-
tion that some relapse cases arise from an undetected ancestral
clone rather than through ongoing mutation of the dominant
diagnostic clone (Inaba et al., 2013).
A key finding of these combined genetic and functional studies
was that genotype influences L-IC frequency. B-ALL samples
with CDKN2A/B mutation had an L-IC frequency that was on
average 1,000-fold higher than that of samples without these
mutations (Notta et al., 2011). Mouse models with defined ge-
netic lesions also support the conclusion that genotype can influ-
ence T-IC properties. For example, three differentmousemodels
of lung cancer showed variability with respect to the phenotype
of the T-IC (Curtis et al., 2010). In tumors initiated with activa-
tion of oncogenic K-rasG12D and p53 deficiency, cells expressing
Sca-1 could be prospectively purified as T-IC. However, inCell Stem Celladenocarcinomas driven by K-rasG12D
alone, Sca-1 did not significantly enrich
for T-IC activity. Furthermore, for adeno-
carcinomas expressing a mutant human
EGFR transgene, only Sca-1-negative
cells harbored T-IC activity (Curtis et al.,
2010). This study predicts that the same
markers may not identify CSCs in all pa-
tient samples of a specific tumor type.
Importantly, while CSC markers varied
between the different genetic tumormodels, a hierarchical organization was present within each
model, supporting the notion that on top of genetic diversity,
nongenetic functional variability governs tumor growth. Thus,
thesemodels highlight the influence that the genetic background
of a cancer has on CSC properties.
Collectively, these data indicate that T-ICs are not static en-
tities but can evolve. When they evolve and acquire additional
mutations, the T-IC frequency can increase, indicating that the
increasing genetic burden can lead to increased self-renewal
as well as interfere with the malignant maturation process.
Thus, a dynamic model emerges where early in tumor progres-
sion the tumor is a close caricature of the developmental hierar-
chy of the tissue from which it arose, with a minority T-IC and a
high proportion of more differentiated non-T-IC (Figure 2). As
T-IC accumulate advantageous mutations, these perturb differ-
entiation processes further and increase self-renewal such that
the T-IC expand in the subclone, reading out as having increased
frequency in assays. As tumors progress, the mutational burden
becomes high resulting in impairment of the remaining matura-
tion programs and even higher capacity for self-renewal, and
further expansion of cells possessing T-IC properties. In this
model, as cancers progress, tumor hierarchies become shal-
lower within genetic subclones. In some cases, once the clone
has progressed to such an advanced state, the frequency of
T-IC may be so high that the tumor subclone essentially
becomes functionally homogeneous without evidence of a
hierarchy. If this model is accurate, it could contribute a plausible
explanation for why independent studies of the same tumor type
(for example, melanoma) might yield different results between14, March 6, 2014 ª2014 Elsevier Inc. 285
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at different stages of progression might not be comparable
because their mutational burden differs.
Because mutations arise in both T-IC and non-T-IC popula-
tions, and because only T-IC contain long term propagating
and self-renewing cells, it is likely that most T-IC arise from the
genetic evolution of T-IC and not from the non-T-IC compart-
ment, which lacks self-renewal. However, it is also possible
that occasionally mutations will arise in non-T-IC that endow
them with self-renewal capacity and convert them into T-IC.
Therefore, during progression, the T-IC compartment might be
a composite of T-IC generated from evolving T-IC, as well as
some newly generated T-IC. Different tumors and mutations
might have higher rates of non-T-IC conversion to T-IC than
others. Computational simulations have shown that non-T-IC
may also be important for the overall robustness of T-ICs, while
T-ICs are the units of selection during the evolution of a cancer
(Greaves, 2013; Sprouffske et al., 2013). We propose this revised
model as a unification of the genetic evolution and develop-
mental/CSC hierarchy models. Indeed, the other nongenetic
determinants described above (noise, stochasticity, plasticity,
TME) can also be accommodated as mechanisms that can
convert non-T-IC into T-IC. Overall, this unified model provides
a framework for future studies to determine which tumor types
might follow these predictions.
Challenge with Studying Solid Tumors
Solid tumor studies pose a particular challenge to capture the
subclonal diversity present within the parent tumor. Several
studies have shown that genetic subclones are topographically
separate (Gerlinger et al., 2012; Yachida et al., 2010). As such,
biopsy specimens that are used for research may not be repre-
sentative of the entire parent tumor. For solid tumors, sampling
multiple, different geographical regions from the primary tumor
will be important for capturing distinct genetic subclones. This
may not be possible for all solid tumors, but it will be instrumental
in determining the extent of genetic subclonal variability and it
will aid in interpreting concurrent CSC studies. Even if one biopsy
is taken, it may represent several genetic subclones that will
require separation into individual clones before CSC studies
can be carried out on each subclone. While subclonal lineage
relationships can be reconstructed using deep sequencing,
another method by which subclones can be separated is by
transplanting cancer cells at clonal cell doses over multiple re-
cipients (Figure 5). Following engraftment of independent ge-
netic subclones, CSC-related questions can then be addressed
in each subclone. Thus, even if the entire tumor specimen is not
sampled for genetic analysis, CSC studies will be carried out at
least on some of the subclones present in the parent tumor.
Studying CSCs in the context of independent subclones is
important as all subclones and the corresponding CSCs need
to be eradicated for successful therapy.
Linking Stemness, Prognosis, and Therapy
If CSCs represent the unit of selection in tumors, as discussed
above, then clinically relevant parameters including survival
must be more closely related to the properties of CSCs than to
non-CSCs. Testing this concept requires understanding the
unique molecular circuitry of T-IC as compared to non-T-IC.286 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.Wehave recently reported initial identification of an L-IC-specific
transcriptional signature through gene-expression analysis of 16
AML samples that were each separated into four fractions and
the L-IC activity of each fraction tested in optimized xenograft
assays (Eppert et al., 2011). Functional L-IC testing was essential
because the cell fraction(s) that contained L-IC were variable for
each sample. The L-IC signature was prognostic for overall sur-
vival across a wide spectrum of AML patients, providing strong
validation of the CSC model and of the clinical relevance of
L-IC. In parallel, we carried out analysis of the transcriptional
landscape of the entire spectrum of normal human HSC and pro-
genitors. We found that HSC and L-IC gene-expression signa-
tures converged on a shared stemness signature that was also
highly prognostic (Eppert et al., 2011). We recently expanded
this study and have completed gene-expression profiling of
functionally defined L-IC and non-L-IC containing fractions
from an additional 84 AML patient samples. Gene-expression
analysis of this more representative data set generated a power-
ful signature that is highly prognostic when tested on approxi-
mately 1,000 AML patients in four independent cohorts. The
fact that a single signature has such high prognostic power
across a diverse spectrum of patients, each with distinct genetic
mutations, establishes that stemness is a central biological
property or process upon which many driver mutations coa-
lesce. Recently, stemness signatures have been developed
from normal stem cells in solid tissues including the intestine
and breast (Merlos-Sua´rez et al., 2011; Pece et al., 2010). Similar
to our leukemia results, the stem cell signatures were highly pre-
dictive of T-IC content and patient outcome. Overall, these early
studies support a link between genetics and stemness and high-
light the need to develop more stemness signatures from a wide
distribution of tumor types to test the generalizability of this
concept.
Strong evidence is emerging to support a link between
stemness and therapy resistance in glioblastoma, colon cancer,
breast cancer, and numerous other tumors, where studies show
that T-IC fractions are more resistant to therapy compared to
non-T-IC (Bao et al., 2006; Diehn et al., 2009; Ishikawa et al.,
2007; Saito et al., 2010; Viale et al., 2009; Zhang et al., 2010).
Indeed, T-IC possess as a number of biological properties that
distinguish them from the remainder of tumor cells; not only
resistance to treatment (Bao et al., 2006; Li et al., 2008; Tehran-
chi et al., 2010) but also evasion of cell death (Majeti et al., 2009;
Todaro et al., 2007) and dormancy (Kreso et al., 2013). While
many of these papers involve in vitro or xenograft assays, patient
data is also accumulating. In patients with 5q– myelodysplastic
syndrome (MDS), complete remission can be achieved with
lenalidomide treatment but patients invariably relapse. FISH
analysis of bone-marrow specimens obtained prior to therapy
showed that both progenitor (CD34+CD38+) and L-IC (CD34+
CD38Thy1+) compartments harbored the 5q– deletion (Tehran-
chi et al., 2010). In most patients, the L-IC compartment was
resistant to lenalidomide treatment while progenitor cells were
eliminated. In one patient with clinically advanced disease,
both L-IC and progenitor cell compartments were resistant to
treatment, suggesting either that therapy selected for a genetic
subclone with an L-IC population that is not marked by the
CD34+CD38Thy1+ surface markers or that with additional
mutations non-CSCs gained L-IC properties. Recent studies in
Cell Stem Cell
Reviewmultiple myeloma, a lymphoid malignancy, have also shown
that a newly identified L-IC population is resistant to protea-
some inhibitor treatment compared to the bulk tumor cells
(Leung-Hagesteijn et al., 2013). Collectively, these studies high-
light the interplay between genetics and CSC properties that
drive clinical parameters such as therapy response and ulti-
mately survival.
The emerging evidence linking stemness to prognosis and
therapy failure suggests that therapeutic targeting of determi-
nants of stemness might be an effective means to eradicate
T-IC and prevent recurrence. Although there is still considerable
uncertainty as to how stemness is regulated, several regulators
including Bmi-1 have been strongly linked to self-renewal and
have been implicated in the maintenance of stem cells in several
tissues (Lessard and Sauvageau, 2003; Molofsky et al., 2003;
Park et al., 2003). We have found that human colorectal T-IC
function is dependent on BMI-1. Downregulation of BMI-1 in-
hibits the ability of colorectal T-ICs to self-renew, resulting in
abrogation of their tumorigenic potential (Kreso et al., 2014).
Treatment of primary colorectal cancer xenografts with a small
molecule BMI-1 inhibitor resulted in colorectal T-IC reduction
with long-term and irreversible impairment of tumor growth.
These studies point to the need to attempt clinically feasible tar-
geting of this and other predicted components of the self-
renewal machinery. Because stemness-associated factors are
likely shared between normal stem cells and CSCs, successful
eradication of CSCs will require understanding to what extent
CSCs differ from normal stem cells to minimize the impact of
therapies on normal stem cell function.
The Road Ahead
Over the last several decades, there has been a revolution in our
understanding of cancer growth. Advances in sequencing tech-
nologies have paved the way to deciphering the tumor genome.
It is becoming increasingly clear that a tumor does not have one
single tumor genome, but instead comprises multiple genomes
that belong to distinct subclones. These subclones may evolve
in parallel over the lifetime of a cancer and contribute to intratu-
moral heterogeneity. However, even within single genetic sub-
clones, not all cells function equally: some cells retain capacity
for self-renewal and long-term clonal maintenance, some lay
dormant, some fuel tumor growth, and most tumor cells are
postmitotic and destined for clearance.
Despite the apparent complexity, there are unifying principles
rooted in developmental hierarchies that can guide our approach
to targeting cancer. The litmus test for defining a dangerous can-
cer clone is whether the clone contains cells that exhibit unlim-
ited growth potential. Unlimited growth potential is exhibited
by the most primitive cells, which possess stemness properties
such as self-renewal. Thus, by understanding stemness proper-
ties within tumors, we will be able to gain insight into the most
important cells that can drive sequential rounds of tumor growth.
Work in several tumor types has shown that cells with stem cell
properties are equipped with innate machinery that protects
them from radiation and chemotherapy. As well, stem cell
gene-expression programs correlate with patient outcome,
further supporting the relevance of stemness properties in can-
cer. By delineating genetic from nongenetic stemness influ-
ences, we will be able to tease apart the unique aspects of tumorgrowth and ultimately gain a unified understanding of how
diverse genetic subclones, each with their own superimposed
developmental hierarchy, coordinate tumor maintenance.
In nature, evolution creates biodiversity and this in turn makes
an entire ecosystem robust. In cancer, diversity within tumor
cells at the genetic and functional level together with their coex-
istence with the microenvironment also increases tumor fitness,
allowing tumor cells to offset survival pressures imposed by ther-
apy. More effective therapies will require gaining insight into this
diversity.
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